Paratek Corp., Nabriva Therapeutics, and Cempra all appear on course to bring new antibiotics to market soon. But which could be the best bet for your portfolio now?
News & Analysis: Cempra
The pharmaceutical company received an FDA rejection of the worst kind.
The biotech receives an analyst downgrade ahead of an FDA decision.
FDA uncertainty plagues the biotech's share price.
The biotech isn't having a good week.
A manufacturing delay has investors reassessing the biotech's current value.
Here's a look at the reasons why shares of Cempra jumped last month.